Pressed Into Action: Measuring Pharma’s Reputation Reversal
Biopharma in 2021: Big Gains, Volatile Values
The Resilience of R&D: Pharma Posted Record Output in 2021
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
Biopharma Stocks, M&A Sputter Amid More Headwinds
Pandemic Accelerates CTV Ascent: How Pharma Can Benefit
The Human Factor in Data Security Breaches
Tapping the Surge in Useful Contingent Labor Market
Aligning the Many Interpretations of ‘Unmet Medical Need’
Califf Has Rare Chance to Rewrite His Legacy
Pharmaceutical Executive, March 2022 Issue (PDF)
A Rocky Road Ahead for New FDA Chief Califf